Leukemia in Black Patients: The Survival and Donor-Match Gap

Leukemia is cancer of the blood and bone marrow. The marrow, the spongy tissue inside your bones, makes abnormal white blood cells that crowd out the healthy cells your body needs to carry oxygen, clot, and fight infection. There are four main types, split by speed (acute or chronic) and by cell line (myeloid or lymphoid). For Black patients, the central problem is not always who gets leukemia. It is who survives it, and a bone-marrow registry that was not built with them in mind.

Leukemia is grouped two ways at once. Acute leukemias grow fast and need treatment within days to weeks. Chronic leukemias grow slowly and may be watched for years. Myeloid leukemias start in the cells that become red cells, platelets, and most white cells. Lymphoid leukemias start in lymphocytes, a type of white cell. Combine those and you get the four:

• Acute myeloid leukemia (AML): the most common acute leukemia in adults. Fast-moving and the type with the most stark racial survival gap.
• Acute lymphoblastic leukemia (ALL): the most common cancer in children, but it affects adults too.
• Chronic myeloid leukemia (CML): driven by a single genetic change (the Philadelphia chromosome) and now often controlled long-term with targeted pills.
• Chronic lymphocytic leukemia (CLL): the most common adult leukemia overall, often slow enough to monitor before treating.

Leukemia is not the same as multiple myeloma, a separate blood cancer that starts in plasma cells and is more common in Black Americans. If you are sorting out a blood-cancer diagnosis, read our guide to multiple myeloma in Black patients.

For several leukemia types, including ALL, incidence is actually lower in Black Americans than white Americans. The danger is in the outcome. In a study of children with high-risk ALL, white patients had a 5-year overall survival of 79% compared with 52% for Black patients, a gap that persisted after accounting for poverty and insurance status (Walsh et al., Pediatric Blood & Cancer, 2017, PMID 27650428).

AML shows the same pattern. Black patients have shorter survival than white patients, and the gap is widest in adults under 60, holding even after adjusting for socioeconomic and molecular features (Bhatnagar et al., Cancer Discovery, 2021, PMID 33277314). When researchers looked deeper, validated proxies for structural racism, measured at the neighborhood level, explained more of the AML survival gap than genetics, comorbidities, healthcare access, or treatment combined (Abraham et al., Blood, 2022, PMID 35061876). In that study Black patients had a 59% higher risk of death despite, on average, younger age and more favorable disease genetics.

Part of the problem is that the evidence base was not built on Black patients. In a systematic review of AML randomized trials, only 4.7% of participants were Black, and Black enrollment fell from roughly 7% in 1990s trials to about 4% in 2010s trials (Loeb et al., Blood Neoplasia, 2025, PMID 40453142). Treatments are tested, dosed, and approved largely on a population that does not include enough of the people who die at higher rates.

Acute leukemia symptoms come from low blood counts, because cancer cells crowd out healthy ones. They can build over days to weeks. Watch for:

• Fatigue, weakness, pale skin, shortness of breath from anemia (low red cells). On brown and Black skin, pallor shows up most in the inner lip, gums, and the lining of the lower eyelid rather than the face.
• Easy bruising or bleeding: frequent nosebleeds, bleeding gums, heavy periods, or tiny red or purple spots from low platelets.
• Frequent or stubborn infections and fever from a shortage of normal white cells.
• Night sweats, unexplained weight loss, loss of appetite.
• Bone or joint pain as marrow fills with cancer cells.
• Swollen lymph nodes in the neck, armpit, or groin.

These overlap with far more common conditions. Fatigue and pallor often trace to iron-deficiency anemia, not cancer. Our guide to iron-deficiency anemia in Black women covers that. The point is not to panic. It is to get a blood count when symptoms stack up or refuse to clear.

Diagnosis starts cheap and ends precise. A complete blood count (CBC) is the first clue: too many, too few, or abnormal-looking white cells. A blood smear lets a pathologist look at the cells under a microscope. The definitive test is a bone marrow biopsy and aspiration, usually from the back of the hip, which confirms leukemia and identifies the type. Cytogenetic and molecular testing then reads the cancer's genetics, the Philadelphia chromosome, NPM1, IDH2, FLT3 and others, which decide prognosis and which targeted drug fits. Black patients have a documented history of delayed diagnosis and referral, so pushing for a timely CBC and a hematology referral matters.

Treatment depends on type. Chemotherapy remains the backbone for acute leukemias. Targeted therapy has transformed some types: CML is often controlled with daily tyrosine-kinase-inhibitor pills, and newer targeted drugs treat specific AML mutations. Allogeneic stem-cell transplant, replacing diseased marrow with a healthy donor's blood-forming cells, can cure high-risk leukemia. That is where the deepest disparity lives.

A transplant requires a donor whose human leukocyte antigen (HLA) markers closely match the patient's. Because HLA types cluster by ancestry, patients are far likelier to match donors of similar background, and the registry skews heavily white. A landmark analysis of the U.S. registry found that a white patient of European descent had about a 75% to 79% chance of finding a fully matched (8/8) unrelated adult donor. For Black Americans, that likelihood dropped to roughly 16% to 29% (Gragert et al., New England Journal of Medicine, 2014, PMID 25054717). Black and Hispanic registered donors also drop out at higher rates when called, which lengthens the wait.

This is the rare disparity an ordinary person can shrink directly. Joining the marrow registry takes a cheek swab and a few minutes. Every Black, multiracial, and mixed-ancestry person who registers raises the odds that the next Black patient finds a match. You may never be called. If you are, you may save a stranger's life. The U.S. registry is run by NMDP (formerly Be The Match) at my.nmdp.org.

Start with a primary-care visit and a CBC. If results are off, you want a hematologist-oncologist, ideally at a center that treats leukemia regularly and runs clinical trials, because trial access is part of the survival gap. Ask whether you are a candidate for a trial and whether transplant is on the table early. A clinician who listens and refers fast is worth seeking out. You can find a Black or Black-serving clinician in our directory to start that relationship before a crisis forces it.